GLP-1 vs Metformin: Weight Loss, A1C, and PCOS Compared [2026]

GLP-1 drugs like semaglutide and metformin both lower blood sugar, but they are not the same kind of medicine, and they do not produce the same results. Metformin is a cheap, decades-old pill that nudges weight down a little and lowers A1C modestly. GLP-1 receptor agonists are newer injectable or oral drugs that cause much larger weight loss and bigger A1C drops, but cost far more and carry a heavier side-effect load.

This guide compares the two head to head across the three things people actually search for: weight loss, blood sugar control in type 2 diabetes, and polycystic ovary syndrome (PCOS). The evidence is graded honestly, including where it is thin or mixed.

The Short Version: Two Different Tools

Metformin and GLP-1 drugs get lumped together because both are used in type 2 diabetes and both can help with weight. That is where the similarity ends.

Metformin works mostly in the liver. It lowers the amount of sugar your liver dumps into the blood and makes your body a little more sensitive to insulin. It is taken as a daily pill, costs a few dollars a month, and has a 60-plus-year safety record.

GLP-1 receptor agonists copy a gut hormone called glucagon-like peptide-1. They tell the pancreas to release insulin when blood sugar is high, slow down how fast the stomach empties, and act on appetite centers in the brain so you eat less. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound — technically a dual GIP/GLP-1 drug) are the best-known examples.

The practical difference: metformin is a modest, foundational drug. GLP-1 drugs are powerful weight-loss and glucose drugs that cost more and ask more of your body.

Feature	Metformin	GLP-1 (e.g., semaglutide)
Drug class	Biguanide	GLP-1 receptor agonist
Form	Daily pill	Weekly injection (or daily pill)
Average weight loss	~2-3 kg (about 2-3%)	~12-15% at full dose
A1C reduction (typical)	~1.0-1.5%	~1.0-1.8%
Monthly cost (US, cash)	~$4-15	~$500-1,300 (brand)
Main side effects	Diarrhea, nausea, B12 drop	Nausea, vomiting, constipation
Cardiovascular outcome benefit	Suggested (older data)	Proven in trials
Years on market	60+	~20 (older agents); newer ones recent

The numbers above are typical ranges from clinical trials and labels. Your results depend on dose, how long you stay on the drug, and whether you also change diet and activity.

How Each Drug Works

Metformin's mechanism

Metformin's main job is to quiet down the liver. In type 2 diabetes, the liver releases too much glucose. Metformin reduces that output. It also improves insulin sensitivity in muscle and may change gut bacteria and gut hormone signaling in ways researchers still do not fully understand.

What it does NOT do well is cause large weight loss. Metformin slightly reduces appetite for some people, but it does not flood the brain with satiety signals the way GLP-1 drugs do. Any weight change is small and gradual.

GLP-1's mechanism

GLP-1 drugs hit several targets at once:

• Pancreas: boost insulin release, but only when blood sugar is high, which is why they rarely cause low blood sugar on their own.
• Stomach: slow gastric emptying, so food sits longer and you feel full.
• Brain: act on appetite and reward centers, cutting hunger and food "noise."

That brain-and-gut combination is why GLP-1 drugs produce weight loss that metformin cannot match. The same slowing of the stomach also explains the nausea many people feel early on.

Tirzepatide adds a second hormone target, GIP, which appears to push weight loss even higher in head-to-head diabetes trials. For a deeper breakdown, see our semaglutide vs tirzepatide comparison.

One more mechanism note that matters for real life: because GLP-1 drugs only trigger insulin release when blood sugar is already high, they rarely cause dangerous low blood sugar on their own. Metformin shares that trait. This is part of why both are considered safer starting drugs than older agents like sulfonylureas, which force insulin out regardless of blood sugar and can drop it too far. The risk picture changes when either drug is stacked on top of insulin or a sulfonylurea — then low blood sugar becomes a real possibility and doses usually need to come down.

Weight Loss: Not a Close Contest

This is the comparison where the gap is widest, and it is worth being blunt about it.

Metformin: In the long-running Diabetes Prevention Program and its follow-up study, people taking metformin lost roughly 2 to 3 kg on average and kept off about 2.5 kg over many years — modest but durable weight loss tied to how consistently they took the drug (DPPOS, Diabetes Care 2012). That is real, but it is small. For most people it works out to a few pounds, not a dress size.

GLP-1 drugs: In the STEP 1 trial, adults with overweight or obesity (without diabetes) taking semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, versus 2.4% on placebo, and 86% lost at least 5% (Wilding et al., NEJM 2021). Tirzepatide trials have pushed average loss above 20% at the top dose.

Put plainly: at full doses, GLP-1 drugs produce roughly 4 to 6 times the weight loss of metformin. There is no honest reading of the data where metformin competes for pure weight loss.

Honest caveat: Direct, randomized head-to-head trials of metformin alone versus a GLP-1 drug alone for weight loss in people without diabetes are limited. Most of the comparison comes from separate trials, not the same study. The direction is not in doubt, but the exact size of the gap varies by population. You can scan the primary literature on semaglutide versus metformin here.

Outcome	Metformin	Semaglutide (2.4 mg)
Average weight loss	~2-3%	~15%
Reached 5%+ loss	A minority	~86%
Reached 10%+ loss	Rare	Majority
Weight regain after stopping	Small rebound	Large rebound common

That last row matters. When people stop a GLP-1 drug, much of the lost weight tends to come back. Metformin's smaller loss is also easier to maintain. Neither drug is a cure you take once.

Blood Sugar and A1C in Type 2 Diabetes

Here the contest is closer, but GLP-1 drugs still edge ahead on raw glucose lowering — and pull far ahead on outcomes beyond glucose.

Metformin typically lowers A1C by about 1.0 to 1.5 percentage points as a starting drug. It has been the default first pill for type 2 diabetes for decades because it is cheap, safe, weight-neutral-to-helpful, and does not cause low blood sugar by itself.

GLP-1 drugs lower A1C by roughly 1.0 to 1.8 percentage points depending on the agent and dose, and they do it while also driving weight down. In the SUSTAIN trial program, semaglutide added to metformin lowered A1C more than several common comparison drugs.

So on A1C alone, the two are in a similar ballpark, with GLP-1 drugs usually a bit stronger at higher doses. The honest read is that for someone whose blood sugar is only modestly above target, metformin often gets the job done. For someone who is far above target or who also needs to lose a lot of weight, a GLP-1 drug does double duty in a way metformin cannot.

There is a second, quieter advantage to GLP-1 drugs in diabetes that often gets lost in the A1C debate: they lower blood sugar while pulling weight down, and in many people they also nudge blood pressure and triglycerides in the right direction. Metformin is weight-neutral to mildly weight-lowering, which is good, but it does not reshape the whole metabolic picture the way a high-dose GLP-1 drug can. For a person whose diabetes is driven largely by excess weight, that distinction is the whole ballgame.

Where guidelines now stand

The bigger shift is in what guidelines recommend. For years, metformin was the automatic first drug for almost everyone. That is changing.

The American Diabetes Association's 2026 Standards of Care still call metformin a reasonable foundational therapy, but they say that for people with type 2 diabetes who also have heart disease, high cardiovascular risk, heart failure, or chronic kidney disease, a GLP-1 drug and/or SGLT2 inhibitor with proven benefit should be used regardless of A1C and regardless of whether the person is on metformin (ADA Standards of Care 2026, Ch. 9).

In other words: metformin is no longer automatically "first" for high-risk patients. The decision now starts with what other conditions you have, not just your blood sugar number. Our tirzepatide vs semaglutide for diabetes guide covers how the two GLP-1-class options compare for A1C specifically.

Scenario	What guidelines lean toward
New T2D, no heart/kidney disease, cost-sensitive	Metformin first
T2D + heart disease or high CV risk	GLP-1 and/or SGLT2, independent of A1C
T2D + obesity as the main problem	GLP-1 (or dual GIP/GLP-1) often favored
T2D + kidney disease	SGLT2 and/or GLP-1 with proven benefit

PCOS: The Most Nuanced Comparison

PCOS is where the question gets genuinely complicated, and where the evidence for GLP-1 drugs is newest and weakest. Be careful with confident claims here.

Metformin has been used in PCOS for decades. It does not treat PCOS directly, but it targets the insulin resistance that drives much of the condition. The 2023 International PCOS Guideline recommends metformin mainly for metabolic features — weight, insulin resistance, and helping some women with cycle regularity — while combined oral contraceptives remain first-line for irregular periods and excess androgen symptoms (2023 International PCOS Guideline, Eur J Endocrinol). Metformin is cheap, has a long track record, and is considered safe.

GLP-1 drugs are newer to PCOS and used off-label. The logic is strong: many women with PCOS have obesity and insulin resistance, and losing weight improves nearly every PCOS feature, including ovulation. GLP-1 drugs produce far more weight loss than metformin, so on paper they should help.

The early trial evidence supports combining them rather than picking one. A 2025 randomized controlled trial in overweight or obese women with PCOS compared metformin alone against metformin plus semaglutide; the combination produced greater improvements in body weight and metabolic measures than metformin by itself (Reprod Biol Endocrinol 2025). A small 2026 pilot study pointed in the same direction for weight and fertility signals.

Honest grading of the PCOS evidence:

• Most studies are small, short (12 to 40 weeks), and focus on weight and hormones rather than the outcomes women care most about, like reliable ovulation, pregnancy, and live birth.
• GLP-1 drugs are not approved for PCOS. Use is off-label.
• GLP-1 drugs are not safe in pregnancy and the labels advise stopping before trying to conceive, which is a real problem for women using them to improve fertility. Plan timing with a clinician.
• The current weight of expert opinion treats GLP-1 drugs as an add-on for the weight and metabolic side of PCOS, not a replacement for metformin or contraceptives.

So for PCOS, this is not "GLP-1 beats metformin." It is closer to "metformin remains the established metabolic drug, and GLP-1 drugs are a promising but still-unproven add-on, mainly when obesity is the central problem." For the deeper dive, see our pages on semaglutide for PCOS and off-label use and GLP-1 results by subgroup including PCOS. You can also browse the PCOS GLP-1 meta-analysis literature.

Side Effects and Safety

Both drugs cause stomach problems, but the pattern and severity differ.

Metformin:

• Diarrhea, gas, nausea, and stomach cramps, especially when starting. Extended-release versions and taking it with food help.
• A small drop in vitamin B12 over years of use; periodic testing is reasonable.
• Lactic acidosis is the feared but rare risk. Metformin is not recommended when kidney function (eGFR) falls below 30, and it is paused around surgery, severe illness, or imaging dye.

GLP-1 drugs:

• Nausea, vomiting, diarrhea, and constipation are common, usually worst early and easing with slow dose increases.
• Gallbladder problems and, rarely, pancreatitis.
• They carry a boxed warning against use in people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, based on rodent studies (Wegovy (semaglutide) prescribing information, DailyMed).
• Muscle loss is a real concern with rapid weight loss; protein intake and resistance training matter.
• They should generally be stopped before pregnancy.

Safety topic	Metformin	GLP-1
GI upset	Common, usually mild	Common, can be moderate
Low blood sugar alone	Very rare	Very rare
Serious rare risk	Lactic acidosis	Pancreatitis, thyroid warning
Vitamin issues	B12 depletion	Nutrient gaps from eating less
Kidney limit	Avoid if eGFR <30	Used in many kidney patients

A practical point: low blood sugar risk rises sharply if either drug is combined with insulin or sulfonylureas. That is a dosing conversation for your prescriber, not a DIY adjustment.

Cost and Access

This is often the deciding factor.

Metformin is generic and costs roughly $4 to $15 a month, frequently covered with a tiny copay. GLP-1 brand drugs run $500 to over $1,300 a month at cash price, and insurance coverage for weight loss specifically is spotty. Coverage for diabetes is better than coverage for obesity.

That cost gap is why many treatment plans start with metformin and add or switch to a GLP-1 drug only when needed and affordable. If price is your main barrier, see our guides on the cheapest GLP-1 options without insurance and the broader GLP-1 side effects guide.

Access is not only about the sticker price. Metformin is a pill you can fill at any pharmacy with no special approval. Brand GLP-1 drugs often need prior authorization, can be hit by supply shortages, and may require step therapy — meaning your insurer makes you try and fail on a cheaper drug like metformin first. That "fail first" rule is one more reason metformin frequently stays in the picture even when a GLP-1 drug is the long-term goal. Some people also turn to compounded versions to cut cost, which carries its own legal and safety questions worth understanding before you start.

What the Trials Don't Tell You

Clinical trials measure averages under near-ideal conditions. Real life is messier, and a few gaps are worth naming so you set honest expectations.

First, trial participants get coaching, free drugs, and close follow-up. Real-world weight loss on both drugs tends to run lower than the trial headline numbers, partly because people miss doses, stop early from side effects, or cannot afford to continue.

Second, most weight-loss trials run 16 to 68 weeks. We have less high-quality data on what happens over five or ten years, especially for the newest GLP-1 drugs. Metformin, by contrast, has decades of long-term safety data — that maturity is a genuine point in its favor even though its effect is smaller.

Third, neither drug fixes the behavior underneath. Both work far better paired with a protein-forward diet and some resistance training, and both lose ground when those habits slip. The drug is a tool, not the whole plan.

Fourth, head-to-head data is thinner than the confident internet comparisons suggest. Much of what looks like a direct "metformin vs GLP-1" verdict is actually stitched together from separate trials in different populations. The direction of the gap is clear; the precise size in your specific situation is not.

Who Each Drug Is For

Metformin makes the most sense if you:

• have new type 2 diabetes without heart or kidney disease
• want a cheap, well-understood first step
• have PCOS and want an established metabolic drug
• only need modest weight help
• cannot afford or tolerate a GLP-1 drug

A GLP-1 drug makes the most sense if you:

• need substantial weight loss, not a few pounds
• have type 2 diabetes plus heart disease, high cardiovascular risk, or kidney disease
• have obesity as your central health problem
• have not reached goals on metformin alone
• can manage the cost and the side effects

Using both together is common and often the most effective route, especially in type 2 diabetes and in PCOS with obesity. They work by different mechanisms, so the effects add up. Many people end up on metformin plus a GLP-1 rather than choosing one.

The Bottom Line

For pure weight loss, GLP-1 drugs win decisively — there is no real contest. For blood sugar, they are similar to metformin on A1C but pull ahead on heart and kidney outcomes, which is why guidelines now reach for them earlier in high-risk patients. For PCOS, metformin remains the established metabolic option and GLP-1 drugs are a promising but still-unproven add-on, best reserved for when obesity drives the picture and pregnancy is not imminent.

The honest summary: this is rarely an either/or. Metformin is the cheap foundation; GLP-1 drugs are the powerful, pricier upgrade. The right choice depends on your weight goals, your other conditions, your budget, and your tolerance for side effects.

Frequently Asked Questions

Is metformin a GLP-1 drug?

No. Metformin is a biguanide that works mainly on the liver. GLP-1 receptor agonists like semaglutide copy a gut hormone and act on the pancreas, stomach, and brain. They are completely different drug classes that happen to both be used in type 2 diabetes.

Can I take metformin and a GLP-1 drug at the same time?

Yes, and it is common. They work by different mechanisms, so combining them often lowers blood sugar and supports weight loss more than either alone. This combination is standard in type 2 diabetes and is being studied in PCOS. Dosing should be managed by your clinician, especially if you also use insulin.

Which is better for PCOS, metformin or a GLP-1 drug?

Metformin is the established metabolic drug for PCOS with the longest track record, while GLP-1 drugs are a newer off-label add-on. Early trials suggest adding a GLP-1 to metformin improves weight and metabolic markers more than metformin alone, but the evidence is still small and short, and GLP-1 drugs are not safe during pregnancy.

How much more weight will I lose on a GLP-1 versus metformin?

In trials, metformin produces about 2-3% body weight loss, while semaglutide produced about 15% and tirzepatide even more. That is roughly 4 to 6 times the weight loss at full GLP-1 doses. Real-world results are usually somewhat lower and depend on dose and how long you stay on the drug.

Will I keep the weight off if I stop these drugs?

Metformin's smaller weight loss tends to be more durable while you keep taking it. With GLP-1 drugs, studies consistently show that much of the lost weight returns after stopping. Neither drug is a one-time fix; both work as long as you take them and pair them with diet and activity changes.

---

This article is for general education and is not medical advice. Talk to a licensed clinician before starting, stopping, or combining any medication.